Great Point Partners LLC Aerovate Therapeutics, Inc. Transaction History

Great Point Partners LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.68 - $29.57 $2.65 Million - $4.44 Million	-150,000 Reduced 14.46%	887,690 $26.2 Million
Q4 2023 Feb 14, 2024	SELL	$9.58 - $24.25 $512,941 - $1.3 Million	-53,543 Reduced 4.91%	1,037,690 $23.5 Million
Q3 2023 Nov 14, 2023	BUY	$12.9 - $18.88 $2.05 Million - $3 Million	159,075 Added 17.07%	1,091,233 $14.8 Million
Q2 2023 Aug 14, 2023	BUY	$15.63 - $22.01 $2.76 Million - $3.89 Million	176,538 Added 23.36%	932,158 $16 Million
Q1 2023 May 15, 2023	BUY	$19.17 - $27.7 $7.23 Million - $10.4 Million	377,098 Added 99.62%	755,620 $15.2 Million
Q4 2022 Feb 14, 2023	BUY	$15.92 - $30.52 $6.03 Million - $11.6 Million	378,522 New	378,522 $11.1 Million

27.7M

185K

129K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $51.1M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.